Diagnostics and therapeutics for diseases associated with phosphodi-esterase 1c (pde1c)
AssigneeBayer HealthCare LLC
InventorsStefan Golz, Ulf Bruggemeier, Andreas Geerts
Life of this patent
Estimating the term…
Abstract
The invention provides a human PDE1C which is associated with the cardiovascular disorders, gastrointestinal and liver diseases, cancer disorders, neurological disorders, respiratory Diseases and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, gastrointestinal and liver diseases, cancer disorders, neurological disorders, respiratory Diseases and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of PDE1C as well as pharmaceutical compositions comprising such compounds.
Claims23
A method of screening for therapeutic agents useful in the treatment of a disease selected from the group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, cancer disorders, neurological disorders, respiratory diseases and urological disorders in a mammal comprising the steps of
- i) contacting a test compound with a PDE1C polypeptide,
- ii) detecting binding of said test compound to said PDE1C polypeptide.
A method of screening for therapeutic agents useful in the treatment of a disease selected from the group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, cancer disorders, neurological disorders, respiratory diseases and urological disorders in a mammal comprising the steps of
- i) determining the activity of a PDE1C polypeptide at a certain concentration of a test compound or in the absence of said test compound,
- ii) determining the activity of said polypeptide at a different concentration of said test compound.
A method of screening for therapeutic agents useful in the treatment of a disease selected from the group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, cancer disorders, neurological disorders, respiratory diseases and urological disorders in a mammal comprising the steps of
- i) determining the activity of a PDE 1C polypeptide at a certain concentration of a test compound,
- ii) determining the activity of a PDE1C polypeptide at the presence of a compound known to be a regulator of a PIE1C polypeptide.
A method of screening for therapeutic agents useful in the treatment of a disease selected from the group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, cancer disorders, neurological disorders, respiratory diseases and urological disorders in a mammal comprising the steps of
- i) contacting a test compound with a PDE1 C polynucleotide,
- ii) detecting binding of said test compound to said PDE1C polynucleotide.
A method of diagnosing a disease selected from the group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, cancer disorders, neurological disorders, respiratory diseases and urological disorders in a mammal comprising the steps of i) determining the amount of a PDE1C polynucleotide in a sample taken from said mammal, ii) determining the amount of PDE1C polynucleotide in healthy and/or diseased mammals.
19-20. (canceled)
A pharmaceutical composition for the treatment of a disease selected from the group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, cancer disorders, neurological disorders, respiratory diseases and urological disorders in a mammal comprising a therapeutic agent which regulates the activity of a PDE1C polypeptide, wherein said therapeutic agent is
- i) a small molecule,
- ii) an RNA molecule,
- iii) an antisense oligonucleotide,
- iv) a polypeptide,
- v) an antibody, or
- vi) a ribozyme.
A pharmaceutical composition for the treatment of a disease selected from the group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, cancer disorders, neurological disorders, respiratory diseases and urological disorders in a mammal comprising a PDE1C polynucleotide.
A pharmaceutical composition for the treatment of a disease selected from the group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, cancer disorders, neurological disorders9 respiratory diseases and urological disorders in a mammal comprising a PDE1C polypeptide.
24-26. (canceled)
Dependencies are inferred from the claim text.